Eli Lilly chief executive Dave Ricks at the group's new biologics plant in Limerick with IDA Ireland chief executive Michael Lohan, Minister for Enterprise, Trade and Employment Peter Burke and Limerick site lead Dave Riordan. Photograph: Arthur Ellis
The doubling of Lilly’s investment in the new plant points to its confidence in its portfolio of Alzheimer’s drugs. Manufacturing the active ingredient for those medicines will be the focus of the Limerick plant when it opens. That is expected to be in 2026. It will also supply active drug ingredient for other Lilly biologic medicines.
The company on Thursday also formally opened an $800 million expansion of its Kinsale site which last year started manufacturing Lilly’s diabetes and obesity treatments which are experiencing a surge in demand across the industry.